Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases
8 Pages Posted: 18 Apr 2023
Date Written: April 17, 2023
Abstract
This cross-sectional study compares Medicare & Medicaid spending on and beneficiaries of ultra-rare, rare, common, and non-orphan cancer drugs.
Funding/Support: No funding was received for conducting this study. T.M. was supported by the DKFZ clinician-scientist program. D.T.M. was supported by the Federal Ministry of Education and Research (BMBF) Young Scientist Award the German Cancer Society’s (DKG) Young Talent Award, and by the German Research Foundation (DFG) Travel Grant.
Note:
Funding Information: No funding was received for conducting this study.
Conflict of Interests: The authors declare that they have no conflicts of interest.
Keywords: orphan designation, cancer drug, healthcare expenditure, rare orphans, ultra-rare orphans, common orphans, rare diseases
JEL Classification: I1, I10, I13, I18
Suggested Citation: Suggested Citation